Alexander Sapir
Directeur Général chez FULCRUM THERAPEUTICS, INC.
Fortune : 309 870 $ au 30/04/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Robert Gould | M | 69 | - | |
| Clay Thorp | M | 55 | 22 ans | |
| Eddy Littler | M | - |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | 8 ans |
| Kathryn Haviland | F | 48 | 6 ans | |
| Jonathan Mow | M | 59 | 12 ans | |
| Michael Benkowitz | M | 52 | 13 ans | |
| James Edgemond | M | 56 | 11 ans | |
| Kristopher Hanson | M | 52 | 5 ans | |
| Neil Mathews | M | - |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | 13 ans |
| Richard van den Broek | M | 57 | 5 ans | |
| Katina Dorton | F | 66 | 4 ans | |
| Lawrence Perkins | M | 47 | 2 ans | |
| Mel Hayes | M | 54 | 3 ans | |
| Leslie Leinwand | M | - | - | |
| Susan Arnold | M | 49 | 14 ans | |
| Tommy Thompson | M | 81 | 14 ans | |
| James Collins | M | 58 | 7 ans | |
| Sonja Banks | F | 55 | 3 ans | |
| Richard Giltner | M | 60 | 15 ans | |
| Edmund Harrigan | M | 71 | 6 ans | |
| R. Alan B. Ezekowitz | M | 70 | 8 ans | |
| Alan Musso | M | 62 | 1 ans | |
| Judy Olian | M | 72 | 9 ans | |
| Katherine Klein | M | 67 | 10 ans | |
| James Geraghty | M | 69 | 8 ans | |
| Iain Fraser | M | - | 1 ans | |
| Stuart Cockerill | M | - |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | 13 ans |
| William Humphries | M | 57 | 3 ans | |
| Nancy Hutson | M | 74 | 6 ans | |
| Jeffrey W. Jacobs | M | 61 | 2 ans | |
| Kristina Storey | F | - | 2 ans | |
| Dee Smith | M | - | - | |
| Paul Bruno | M | - | 5 ans | |
| Gregory Tourangeau | M | - | 2 ans | |
| Lee F. Allen | M | 72 | 7 ans | |
| Mani Sundararajan | M | - | 3 ans | |
| Da Liu | M | 53 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | - |
| Raphaël Wisniewski | M | 54 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | - |
| Lawrence Blatt | M | 62 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | - |
| Brett K. Haumann | M | 54 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | - |
| Ken Powell | M | - |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | - |
| Ron Hunt | M | 59 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | - |
| Iain Dukes | M | 65 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | - |
| Naveed Iqbal Siddiqi | M | - |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | 3 ans |
| John Lee | M | 56 | 8 ans | |
| Kim Hazen | F | - | 7 ans | |
| Chau Khuong | M | 48 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | - |
| Curtis Oltmans | M | 60 | 4 ans | |
| Bill L. Nichols | M | - | 6 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Craig R. Smith | M | 77 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 11 ans |
| Dean Mitchell | M | 68 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 1 ans |
| Douglas Blankenship | M | 62 | 1 ans | |
| John Maxim Ferrari | M | 69 | 14 ans | |
| David Zaccardelli | M | 59 | 1 ans | |
| Steven M. Goldman | M | 72 | 2 ans | |
| Bibhash Mukhopadhyay | M | 43 | 2 ans | |
| Nancy Wysenski | F | 66 | 1 ans | |
| John P. Sharp | M | 59 | 6 ans | |
| Peter Klein | M | 46 | 12 ans | |
| Caroline Loewy | F | 58 | 5 ans | |
| Alfred Novak | M | 76 | 2 ans | |
| Roger Jeffs | M | 62 | 2 ans | |
| Jason Hoitt | M | 46 | 1 ans | |
| Kiernan T. DeAngelis | M | 54 | 4 ans | |
| Tracy Newbold | F | - | 6 ans | |
| Lauren Richardson | F | - | - | |
| Scott Moomaw | M | 54 | 5 ans | |
| Ostra Jewell | F | - | 2 ans | |
| L. Smith | M | 57 | 2 ans | |
| Glen Burkhardt | M | 65 | 4 ans | |
| William Spengler | M | 69 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 1 ans |
| Michael York | M | 59 | 3 ans | |
| Martin Auster | M | 49 | 5 ans | |
| Kevin Laliberte | M | 46 | - | |
| Andrew J. Jeanneret | M | 59 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 ans |
| Eugene Jeffrey Sullivan | M | 59 | 5 ans | |
| Richard Kender | M | 68 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | 3 ans |
| Francesca M. Cook | F | 58 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 ans |
| Mark Hahn | M | 61 | 1 ans | |
| Jonathan Birchall | M | 55 | 2 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 67 | 83,75% |
| Royaume-Uni | 13 | 16,25% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Alexander Sapir
- Réseau Personnel